据了解，阳光诺和于2025年8月2日就恒生制药拖欠"盐酸氨溴索注射液""克林霉素磷酸酯注射液"等共计 24个品种的研发费用事项向法院提起诉讼。近日，湖南省衡阳市中级人民法院就该案作出一审判决。 登录新浪财经APP 搜索【信披】查看更多考评等级 北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"）近日发布公告，披露其与湖南恒生制药股 份有限公司（以下简称"恒生制药"）的研发费用合同纠纷一案已收到一审判决。法院判决恒生制药向阳 光诺和支付拖欠的研发费用25.4万元及相应违约金，但驳回了阳光诺和的其他诉讼请求。公告同时指 出，由于公司已对相关款项全额计提坏账准备，本次诉讼结果对当期及期后利润无负面影响。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn ...

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Four Ring Pharmaceutical, has had several of its products included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025), which may influence future sales but will not significantly impact the company's current operating performance [1] Group 1: Product Inclusion - A total of 34 products from the company's subsidiaries, including Beijing Huasu, Shandong Huasu, and Duoduo Pharmaceutical, have been included in the 2025 drug catalog [1] - New products added to the catalog include Sulfate Fish Protein Injection and Compound Pancreatin Powder [1] - Products previously included in the 2024 catalog, such as Bisoprolol Fumarate Tablets and Benidipine Hydrochloride Tablets, will continue to be listed [1] Group 2: Product Changes - Beijing Huasu's "Compound Chlorphentermine Injection" has been removed from the 2025 catalog [1] - Duoduo Pharmaceutical's "Ambroxol Hydrochloride Injection" has been newly included in the catalog [1] Group 3: Market Impact - The future sales of the included products may be affected by changes in the market environment and other factors [1] - The company states that these changes will not have a major impact on its current operating performance [1]

Core Viewpoint - The return of the original brand Mucosolvan (Ambroxol Hydrochloride) to the Chinese market is anticipated in December 2025, following its exit due to registration expiration and increased competition from generic drugs [1][2]. Group 1: Company Background - Mucosolvan was originally developed by Boehringer Ingelheim and launched in Germany in 1978, entering the Chinese market in 1991 [2]. - The product achieved peak sales exceeding 8 billion yuan in China, making it a highly competitive product in the market [2]. - The original manufacturer, Boehringer Ingelheim, ceased the product's registration in China in 2020, leading to its market exit [3]. Group 2: Market Competition - The return of Mucosolvan will face competition from 367 similar drug approvals in China, including significant price competition from generics [6]. - In the 2021 centralized procurement, Boehringer Ingelheim's bid was only a 0.3% price reduction, while competitors like Yunnan Longhai offered a 93.3% reduction [4]. - The market for expectorants is crowded, with other active ingredients available, such as bromhexine and acetylcysteine, which may affect Mucosolvan's market share [6]. Group 3: Future Outlook - The product's return is now under the management of Opella, a company that became independent from Sanofi in May 2025, which retains a 48.2% stake in Opella [4]. - The ability of Mucosolvan to regain consumer trust and willingness to pay a premium in a low-price environment remains uncertain [6]. - The performance of Mucosolvan post-return will be closely monitored, especially regarding its positioning in the OTC market [6].

Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Duoduo Pharmaceutical, has successfully passed the consistency evaluation for Tramadol Hydrochloride Injection, enhancing its market competitiveness and operational performance [1][5]. Group 1: Drug Approval and Details - Duoduo Pharmaceutical received the approval notice for Tramadol Hydrochloride Injection (2ml:100mg) from the National Medical Products Administration [1][2]. - The drug is classified as a chemical drug and is indicated for moderate to severe pain [3][4]. - The consistency evaluation approval allows for changes in the drug formulation, production process, and quality standards [2][4]. Group 2: Market Context and Financial Impact - In 2024, the sales revenue of Tramadol Hydrochloride Injection in domestic sample hospitals was 230 million yuan, with 93 million yuan in the first quarter of 2025 [4]. - Duoduo Pharmaceutical is the sixth company to pass the consistency evaluation for this drug, following five other companies [4]. - The company has invested 7.15 million yuan in research and development for this drug's consistency evaluation project [4]. Group 3: Future Prospects - The approval of Tramadol Hydrochloride Injection is expected to improve the company's market position and operational results [5]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug lifecycle [5].

Core Viewpoint - Zhongguancun announced that its subsidiary, Duoduo Pharmaceutical, has received the drug registration certificate from the National Medical Products Administration for its product, "Ambroxol Hydrochloride Injection," which has passed the drug registration review and approval process [2] Company Summary - Duoduo Pharmaceutical is a subsidiary of Zhongguancun that has successfully developed "Ambroxol Hydrochloride Injection" [2] - The approval from the National Medical Products Administration marks a significant milestone for Duoduo Pharmaceutical in the pharmaceutical industry [2] Industry Summary - The approval of "Ambroxol Hydrochloride Injection" indicates a positive trend in drug development and regulatory approval within the pharmaceutical sector [2] - This development may enhance the competitive positioning of Duoduo Pharmaceutical in the market for respiratory medications [2]

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. has received the drug registration certificate for "Ambroxol Hydrochloride Injection" from the National Medical Products Administration, indicating successful approval for the drug's registration [1] Group 1: Product Details - Ambroxol Hydrochloride has properties that promote mucus clearance and dissolve secretions, aiding in the expulsion of viscous secretions from the respiratory tract and improving respiratory conditions [1] - The injection is clinically applicable for abnormal mucus secretion and poor expectoration function in acute and chronic pulmonary diseases, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, and bronchial asthma [1] - It is also indicated for the preventive treatment of pulmonary complications after surgery and for the treatment of infant respiratory distress syndrome (IRDS) in premature and newborn infants [1] Group 2: Financial Investment - As of the announcement date, the company has invested a total of 2.0558 million yuan in the research and development of the generic drug registration application project for Ambroxol Hydrochloride Injection [1]

Core Viewpoint - The company, Zhongguancun, announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration certificate of Ambroxol Hydrochloride Injection, which is expected to aid in respiratory health [1] Group 1 - The approved drug, Ambroxol Hydrochloride, is known for its properties that promote mucus clearance and dissolve secretions, thereby improving respiratory conditions [1] - The future production and sales of the drug may face uncertainties due to factors such as national policies and market environment [1]

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary Duoduo Pharmaceutical Co., Ltd. has received the drug registration certificate for "Ambroxol Hydrochloride Injection" from the National Medical Products Administration, indicating successful approval for the drug's registration review and approval process [1] Group 1: Product Details - Ambroxol Hydrochloride has properties that promote mucus clearance and dissolve secretions, aiding in the expulsion of viscous secretions from the respiratory tract and improving respiratory conditions [1] - The injection is clinically applicable for abnormal mucus secretion and poor expectoration function in acute and chronic pulmonary diseases, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, and bronchial asthma [1] - It is also indicated for the preventive treatment of pulmonary complications after surgery and for the treatment of infant respiratory distress syndrome (IRDS) in premature and newborn infants [1] Group 2: Financial Investment - As of the announcement date, the company has invested a total of 2.0558 million yuan in the research and development of the generic drug registration application project for Ambroxol Hydrochloride Injection [1]

Core Viewpoint - The 90th National Pharmaceutical Trade Fair showcased Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., highlighting its brand, high-value product matrix, and ecological win-win philosophy [3][4] Group 1: Product Showcase - Zhenbaodao Pharmaceutical exhibited high-quality product lines focusing on cardiovascular, respiratory, and anti-infection treatment areas, including key products like Injection Blood Setong 100mg and Xuechuang Capsule [3] - The company has developed a dual-driven system of "Traditional Chinese Medicine + Chemical Medicine," featuring products such as Compound Qilan Oral Liquid and Injection Ammonium Bromide [3] Group 2: Marketing Strategy - The company emphasized its 2025 "Guangshen Tuo" marketing strategy, which segments regional markets based on product attributes and promotes a model of "recruiting merchants, finding merchants, and servicing merchants" to enhance terminal coverage and sales efficiency [4] - Zhenbaodao Pharmaceutical established a three-tier academic promotion system, integrating medical, market, and data teams to monitor industry trends and provide precise marketing strategies [4] Group 3: Collaborative Ecosystem - The participation in the trade fair demonstrated the company's competitive product pipeline and industrial layout, aiming to build a comprehensive ecosystem of strategic collaboration, resource sharing, and value co-creation [4] - The company plans to continue driving innovation and collaboration, positioning itself to lead the pharmaceutical industry towards higher value creation [4]